Are the high-costs of MS disease-modifying therapies justified?

Gavin Giovannoni, Chris Hawkes, Michael Levy, Emmanuelle Waubant

Research output: Contribution to journalEditorial

Original languageEnglish (US)
Pages (from-to)A3-A5
JournalMultiple Sclerosis and Related Disorders
Volume20
DOIs
StatePublished - Feb 1 2018

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this